RLAY
Relay Therapeutics, Inc. NASDAQ$12.72
Mkt Cap $2.2B
52w Low $2.67
68.6% of range
52w High $17.32
50d MA $11.72
200d MA $7.53
P/E (TTM)
-7.9x
EV/EBITDA
-5.1x
P/B
3.9x
Debt/Equity
0.1x
ROE
-48.8%
P/FCF
-6.2x
RSI (14)
—
ATR (14)
—
Beta
1.58
50d MA
$11.72
200d MA
$7.53
Avg Volume
3.3M
About
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.38 | -0.32 | +15.8% | 9.16 | +5.2% | +12.0% | +6.9% | +7.5% | +10.8% | +5.2% | +2.1% | — |
| Nov 6, 2025 | AMC | -0.39 | -0.43 | -10.3% | 6.53 | -5.4% | -7.4% | -5.5% | -3.7% | -5.5% | -1.2% | +16.8% | — |
| Aug 7, 2025 | AMC | -0.49 | -0.41 | +16.3% | 3.49 | -8.9% | -7.7% | -6.9% | -4.0% | -2.0% | -2.9% | +16.3% | — |
| May 5, 2025 | AMC | -0.50 | -0.46 | +8.0% | 3.32 | -0.9% | -5.1% | -11.1% | -9.6% | -9.6% | -6.3% | -2.7% | — |
| Feb 26, 2025 | AMC | -0.57 | -0.45 | +21.1% | 3.75 | -13.3% | -13.3% | -9.1% | -14.7% | -14.9% | -9.6% | -27.5% | — |
| Nov 6, 2024 | AMC | -0.77 | -0.63 | +18.2% | 6.25 | +1.3% | -1.8% | -0.8% | -1.4% | -5.0% | -7.0% | -26.2% | — |
| Aug 6, 2024 | AMC | -0.73 | -0.69 | +5.5% | 7.19 | -3.1% | -7.9% | -5.4% | -6.8% | -9.5% | -8.8% | -9.7% | — |
| May 2, 2024 | AMC | -0.70 | -0.62 | +11.4% | 7.08 | +23.0% | -0.6% | -0.3% | -4.8% | -8.1% | -10.9% | -4.1% | — |
| Feb 22, 2024 | AMC | -0.76 | -0.67 | +11.8% | 10.57 | +2.5% | -5.4% | -3.9% | -2.6% | -4.6% | -5.2% | -28.8% | — |
| Nov 2, 2023 | AMC | -0.83 | -0.54 | +34.9% | 7.40 | +13.0% | +1.6% | +9.9% | +10.1% | +5.9% | +2.3% | +12.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.03 | $13.17 | +1.1% | -3.5% | -0.5% | -2.4% | — | — |
| Apr 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $14.95 | $14.79 | -1.1% | -12.8% | -15.9% | -13.3% | -14.9% | — |
| Apr 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.95 | $14.79 | -1.1% | -12.8% | -15.9% | -13.3% | -14.9% | — |
| Apr 28 | Goldman Sachs | Maintains | Buy → Buy | — | $14.95 | $14.79 | -1.1% | -12.8% | -15.9% | -13.3% | -14.9% | — |
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $14.95 | $14.79 | -1.1% | -12.8% | -15.9% | -13.3% | -14.9% | — |
| Apr 8 | Barclays | Maintains | Overweight → Overweight | — | $13.48 | $14.00 | +3.9% | +7.6% | +11.3% | +10.8% | +13.2% | +9.4% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.91 | $10.04 | +1.3% | -0.9% | -4.7% | -3.1% | +2.1% | -3.1% |
| Mar 17 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.13 | $10.06 | -0.7% | +1.3% | -2.0% | -1.3% | -2.2% | -3.1% |
| Mar 17 | Citizens | Maintains | Market Outperform → Market Outperform | — | $10.13 | $10.06 | -0.7% | +1.3% | -2.0% | -1.3% | -2.2% | -3.1% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $10.55 | $11.00 | +4.3% | -1.8% | -4.0% | -2.7% | -5.9% | -5.2% |
Recent Filings
8-K · 8.01
!! High
Relay Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Relay Therapeutics announced positive Phase 1/2 data for its zovegalisib triplet combination and plans to advance zovegalisib plus atirmociclib into Phase 3 testing for PI3K-mutated HR+/HER2- metastatic breast cancer.
Apr 27
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Relay Therapeutics' PI3K inhibitor shows clinical progress in advanced breast cancer combination trials, potentially supporting future regulatory approval and revenue growth if efficacy data continues strengthening.
Mar 16
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Relay Therapeutics' board gained flexibility to schedule annual shareholder meetings without advance notice restrictions, potentially reducing shareholder participation opportunities and limiting governance transparency.
Mar 11
8-K
Relay Therapeutics, Inc. -- 8-K Filing
Relay Therapeutics reported 2025 full-year results and provided 2026 guidance, demonstrating disciplined execution as a clinical-stage precision medicine company advancing oncology and genetic disease therapies.
Feb 26
8-K · 8.01
!! High
Relay Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Relay Therapeutics' zovegalisib received FDA Breakthrough Therapy designation combined with fulvestrant for PIK3CA-mutant HR+/HER2- breast cancer, accelerating development and potentially expediting market approval timelines.
Feb 3
Data updated apr 26, 2026 11:00pm
· Source: massive.com